Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 10/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | USP19 | O94966 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9668723 | 0.89 | KDM1A (0.42) | SMN1; SMN2L3MBTL1TP53TSHR | |
| SCHEMBL9668039 | 0.86 | TP53 (0.44) | SMN1; SMN2TP53HPGDTSHRUSP19 | |
| SCHEMBL9668346 | 0.81 | P2RX7 (0.45) | MDM2SMN1; SMN2TP53HPGDTSHR | |
| SCHEMBL9669910 | 0.80 | KDM1A (0.47) | TP53HPGDTSHRUSP19 | |
| Hydrochloric Acid SCHEMBL9669646 | 0.79 | KDM1A (0.46) | TP53HPGDTSHRUSP19 | |
| SCHEMBL9667995 | 0.78 | MEN1 (0.46) | SMN1; SMN2TP53GAARAB9AHPGD | |
| SCHEMBL9669356 | 0.76 | TP53 (0.54) | MDM2SMN1; SMN2TP53HPGDTSHR | |
| SCHEMBL10405021 | 0.75 | HPGD (0.54) | SMN1; SMN2TP53RAB9AHPGDTSHR | |
| SCHEMBL9668508 | 0.75 | MDM2 (0.42) | MDM2TP53 | |
| SCHEMBL9668042 | 0.75 | TP53 (0.57) | SMN1; SMN2TP53HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-0236263-B1 | SUBSTITUTED PYRROLIDINONES | CIBA-GEIGY AG (CH) | 1992-12-30 | — | — | EP | claimed |
| US-4945092-A | Substituted 1-(oxopyrrolidinylalkanoyl)-piperazines useful as nootropics | CIBA-GEIGY CORPORATION (US) | 1990-07-31 | — | — | US | claimed |
| EP-0236263-A2 | Substituted pyrrolidinones | CIBA-GEIGY AG (CH) | 1987-09-09 | — | — | EP | claimed |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0236263-B1 | SUBSTITUTED PYRROLIDINONES | CIBA-GEIGY AG (CH) | 1992-12-30 | — | — | EP | disclosed |
| US-4945092-A | Substituted 1-(oxopyrrolidinylalkanoyl)-piperazines useful as nootropics | CIBA-GEIGY CORPORATION (US) | 1990-07-31 | — | — | US | disclosed |
| EP-0236263-A2 | Substituted pyrrolidinones | CIBA-GEIGY AG (CH) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | MDM2 2377/4885SMN1; SMN2 101/4885L3MBTL1 3941/4885 |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | MYH10, PDGFA, MPL | MDM2 2858/4885SMN1; SMN2 1472/4885L3MBTL1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.